HIV

A new vaccination schedule pumps up the immune response to human immunodeficiency virus, overcoming a barrier that has frustrated vaccine designers.

Scientists identified specific genes that confer protection or vulnerability to various infections, pointing the way to new treatments.

Pathogens invade mucosal surfaces like the nose, but typical vaccines don't mount an immune response there. Newly engineered mucosal vaccines, however, do.

For decades, researchers have tried to craft a successful vaccine for HIV. mRNA vaccines may offer the answer.

Small molecule drugs that trigger the death of cells storing latent viruses are a promising approach for treating HIV. Researchers identified a potent compound in a marine sponge — a more likely source than it may seem.  

Investigating antibodies produced by infectious diseases yields vaccines with broad-acting protection.

From excising integrated viral sequences to modifying stem cells, CRISPR offers new possibilities for developing HIV treatments.

ConserV Bioscience and eTheRNA immunotherapies collaborate on mRNA vaccines for infectious diseases

Merck reports Phase 1 data of its subdermal implant for pre-exposure prophylaxis of HIV-1 infection

Dosing every eight weeks instead of four still  showed continued virologic suppression to 96 weeks